Difference between revisions of "Part:BBa K3582206"
Line 23: | Line 23: | ||
<span class='h3bb'>Sequence and Features</span> | <span class='h3bb'>Sequence and Features</span> | ||
<partinfo>BBa_K3582206 SequenceAndFeatures</partinfo> | <partinfo>BBa_K3582206 SequenceAndFeatures</partinfo> | ||
+ | |||
+ | |||
+ | ===References=== | ||
+ | *1] Cyclotides, a novel ultrastable polypeptide scaffold for drug discovery. (2011, December 1). PubMed Central (PMC). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3330703/ | ||
+ | *2] Poth, A. G. (2013, May 7). Cyclotides as Grafting Frameworks for Protein Engineering and Drug Design Applications. PubMed. https://pubmed.ncbi.nlm.nih.gov/23893608/ | ||
+ | *3] 2. Camarero, J. A. (2019, April 19). The Potential of the Cyclotide Scaffold for Drug Development. MDPI. https://www.mdpi.com/2227-9059/7/2/31/htm#B31-biomedicines-07-00031 | ||
+ | *4] Lau, C.K.Y., Turner, L., Jespersen, J.S., Lowe, E.D., Petersen, B., Wang, C.W., Petersen, J.E.V Lusingu,J., Theander, T.G., Lavstsen, T., Higgins, M.K. (2015) Cell Host Microbe 17: 118 DOI: 10.2210/pdb4V3E/pdb | ||
+ | |||
Latest revision as of 15:38, 22 October 2020
Inhibitory Sequence 2 for EPCR-PfEMP1 Grafted In Cyclotide
This composite biobrick is believed to synthesize the readily deliverable cyclotide drug that could inhibit the 4V3D interaction between the host protein (Endothelial protein C receptor) and the parasite protein (The CIDRa domain from HB3var03 PfEMP). Different components involved in this biobrick are described below:
- 1]BBa_K3582020: C intein is the modified version of the biobrick used by the Heidelberg 2014 team for circularization of the protein.
- 2]BBa_K2333015: Bsa 1 Reversed recognition site
- 3]BBa_K3582023(The cyclotide precursor): The gene coding for five loops of cyclotide Kalata B1 are inserted between the C Intein and the N intein so that it gets circularized after translation.
- Strep II tag(Inbuilt): This tag is inserted in loop 3 of the cyclotide construct to reduce the haemolytic activity of the cyclotide and ease of purification.
- 4]BBa_k3582204: Inhibitory peptide sequence 2 (IS2) grafted in loop 6 of the cyclotide structure to avoid the host-parasite protein interaction. This mutant sequence has a higher affinity for interaction as compared to wild type.
- 5]BBa_K3582021: Bsa 1 recognition site
- 6]BBa_K3582022: N intein is the modified version of the biobrick used by the Heidelberg 2014 team for circularization of the protein.
The inserted scars are basically the pieces of cyclotide precursor in whose loop the inhibitory peptide biobrick and strep II tag is grafted. The final translated protein product obtained using this biobrick is believed to act as a drug for preventing the CD36-PfEMP1 interaction.
Sequence and Features
Assembly Compatibility:
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25INCOMPATIBLE WITH RFC[25]Illegal AgeI site found at 112
- 1000INCOMPATIBLE WITH RFC[1000]Illegal BsaI site found at 143
Illegal BsaI.rc site found at 109
References
- 1] Cyclotides, a novel ultrastable polypeptide scaffold for drug discovery. (2011, December 1). PubMed Central (PMC). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3330703/
- 2] Poth, A. G. (2013, May 7). Cyclotides as Grafting Frameworks for Protein Engineering and Drug Design Applications. PubMed. https://pubmed.ncbi.nlm.nih.gov/23893608/
- 3] 2. Camarero, J. A. (2019, April 19). The Potential of the Cyclotide Scaffold for Drug Development. MDPI. https://www.mdpi.com/2227-9059/7/2/31/htm#B31-biomedicines-07-00031
- 4] Lau, C.K.Y., Turner, L., Jespersen, J.S., Lowe, E.D., Petersen, B., Wang, C.W., Petersen, J.E.V Lusingu,J., Theander, T.G., Lavstsen, T., Higgins, M.K. (2015) Cell Host Microbe 17: 118 DOI: 10.2210/pdb4V3E/pdb